Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
Cancer Discov ; 14(7): 1143-1144, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38946324

ABSTRACT

In this issue, Ryan and colleagues describe the preclinical development of a pan-RAF:MEK molecular glue with superior efficacy, brain penetrance, and tolerability in xenograft models of Ras/Raf/MAPK pathway-driven tumors. See related article by Ryan et al., p. 1190 (1).


Subject(s)
Protein Kinase Inhibitors , Humans , Animals , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/pharmacology , raf Kinases/metabolism , raf Kinases/genetics , Mice , MAP Kinase Signaling System , Mitogen-Activated Protein Kinase Kinases/metabolism , Neoplasms/genetics , Neoplasms/metabolism
2.
Cell Rep ; 27(2): 631-647.e5, 2019 04 09.
Article in English | MEDLINE | ID: mdl-30970263

ABSTRACT

Deregulated signal transduction is a cancer hallmark, and its complexity and interconnectivity imply that combination therapy should be considered, but large data volumes that cover the complexity are required in user-friendly ways. Here, we present a searchable database resource of synthetic lethality with a PI3 kinase signal transduction inhibitor by performing a saturation screen with an ultra-complex shRNA library containing 30 independent shRNAs per gene target. We focus on Ras-PI3 kinase signaling with T cell leukemia as a screening platform for multiple clinical and experimental reasons. Our resource predicts multiple combination-based therapies with high fidelity, ten of which we confirmed with small molecule inhibitors. Included are biochemical assays, as well as the IPI145 (duvelisib) inhibitor. We uncover the mechanism of synergy between the PI3 kinase inhibitor GDC0941 (pictilisib) and the tubulin inhibitor vincristine and demonstrate broad synergy in 28 cell lines of 5 cancer types and efficacy in preclinical leukemia mouse trials.


Subject(s)
Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , RNA, Small Interfering/genetics , Synthetic Lethal Mutations/genetics , Animals , Disease Models, Animal , Humans , Mice , Protein Kinase Inhibitors/pharmacology , Signal Transduction
3.
Nature ; 551(7679): 247-250, 2017 11 09.
Article in English | MEDLINE | ID: mdl-29088702

ABSTRACT

Acquired drug resistance prevents cancer therapies from achieving stable and complete responses. Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells. The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse. We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival. Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.


Subject(s)
Apoptosis/drug effects , Drug Resistance, Neoplasm/drug effects , Glutathione Peroxidase/antagonists & inhibitors , Neoplasms/drug therapy , Neoplasms/pathology , Animals , Antioxidants/metabolism , Drug Evaluation, Preclinical , Female , Humans , Iron/metabolism , Male , Mesoderm/drug effects , Mesoderm/enzymology , Mesoderm/pathology , Mice , Molecular Targeted Therapy , Neoplasms/enzymology , Phospholipid Hydroperoxide Glutathione Peroxidase , Recurrence , Xenograft Model Antitumor Assays
4.
Chemotherapy ; 61(5): 223-35, 2016.
Article in English | MEDLINE | ID: mdl-26910730

ABSTRACT

BACKGROUND: The discovery of mutations in epidermal growth factor receptor (EGFR) has dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths worldwide. EGFR-targeted therapies show considerable promise, but drug resistance has become a substantial issue. METHODS: We reviewed the literature to provide an overview of the drug resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. RESULTS: The mechanisms causing primary, acquired and persistent drug resistance to TKIs vary. Researchers and clinicians, who have used study findings to develop more effective therapeutic approaches, have found that the sequential use of single agents presents a formidable challenge, suggesting that multidrug combinations must be considered. CONCLUSIONS: In the era of precision medicine, oncologists should promptly obtain an accurate diagnosis of drug resistance in each patient to be able to design the most relevant combination therapy to overcome patient-specific drug resistance.


Subject(s)
Drug Resistance, Neoplasm , ErbB Receptors/antagonists & inhibitors , Lung Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , ErbB Receptors/genetics , ErbB Receptors/metabolism , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , ras Proteins/genetics , ras Proteins/metabolism
5.
Pharmacol Res ; 102: 132-7, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26453958

ABSTRACT

Drug resistance is a major obstacle to the success of EGFR-targeted therapy. We recently studied the mechanism by which a small subset of EGFR mutant lung cancer cells remains viable after EGFR inhibition. We found that this drug-tolerant subpopulation develops because EGFR inhibition prevents AKT activity and thus inactivates Ets-1 function. In this article, we discuss how changes in intrinsic cell signaling after EGFR inhibition open a new avenue to drug resistance in NSCLCs, and comment on combined TKI and MEK inhibitor treatment to reduce the probability of emergent resistance to EGFR TKIs.


Subject(s)
Antineoplastic Agents/therapeutic use , Drug Tolerance/physiology , ErbB Receptors/antagonists & inhibitors , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-akt/metabolism , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Drug Resistance, Neoplasm/drug effects , ErbB Receptors/metabolism , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism
6.
Nat Commun ; 6: 6351, 2015 Feb 18.
Article in English | MEDLINE | ID: mdl-25690954

ABSTRACT

While significant effort has been dedicated to the characterization of epigenetic changes associated with prenatal differentiation, relatively little is known about the epigenetic changes that accompany post-natal differentiation where fully functional differentiated cell types with limited lifespans arise. Here we sought to address this gap by generating epigenomic and transcriptional profiles from primary human breast cell types isolated from disease-free human subjects. From these data we define a comprehensive human breast transcriptional network, including a set of myoepithelial- and luminal epithelial-specific intronic retention events. Intersection of epigenetic states with RNA expression from distinct breast epithelium lineages demonstrates that mCpG provides a stable record of exonic and intronic usage, whereas H3K36me3 is dynamic. We find a striking asymmetry in epigenomic reprogramming between luminal and myoepithelial cell types, with the genomes of luminal cells harbouring more than twice the number of hypomethylated enhancer elements compared with myoepithelial cells.


Subject(s)
Breast/metabolism , Epigenesis, Genetic , Gene Expression Regulation , Breast/cytology , Cell Cycle , Cell Differentiation , Cell Separation , Chromatin/chemistry , Chromatin Immunoprecipitation , CpG Islands , Epigenomics , Epithelial Cells/cytology , Exons , Female , Flow Cytometry , Genome, Human , Histones/chemistry , Humans , Introns , Karyotyping , MicroRNAs/metabolism , Sequence Analysis, RNA , Transcription, Genetic
7.
Genome Biol ; 15(4): 112, 2014 Apr 29.
Article in English | MEDLINE | ID: mdl-25001157

ABSTRACT

Recent studies harnessing deep RNA sequencing coupled with other complementary data have revealed the complex nature of metazoan transcriptomes.


Subject(s)
DNA/genetics , Drosophila melanogaster/genetics , Encyclopedias as Topic , Gene Expression Profiling , Genome, Human/genetics , Molecular Sequence Annotation , Regulatory Sequences, Nucleic Acid/genetics , Transcription, Genetic/genetics , Transcriptome/genetics , Animals , Female , Humans , Male
8.
Cell Rep ; 5(2): 546-52, 2013 Oct 31.
Article in English | MEDLINE | ID: mdl-24120863

ABSTRACT

Protein modification by O-linked ß-N-acetylglucosamine (O-GlcNAc) is a critical cell signaling modality, but identifying signal-specific O-GlcNAcylation events remains a significant experimental challenge. Here, we describe a method for visualizing and analyzing organelle- and stimulus-specific O-GlcNAcylated proteins and use it to identify the mitochondrial voltage-dependent anion channel 2 (VDAC2) as an O-GlcNAc substrate. VDAC2(-/-) cells resist the mitochondrial dysfunction and apoptosis caused by global O-GlcNAc perturbation, demonstrating a functional connection between O-GlcNAc signaling and mitochondrial physiology through VDAC2. More broadly, our method will enable the discovery of signal-specific O-GlcNAcylation events in a wide array of experimental contexts.


Subject(s)
Mitochondria/metabolism , Voltage-Dependent Anion Channel 2/metabolism , Acetylglucosamine/metabolism , Animals , Cell Line , Electrophoresis, Gel, Pulsed-Field , Fluorescent Dyes/chemistry , Glycoproteins/metabolism , Glycosylation , HEK293 Cells , Humans , Jurkat Cells , Mice , Proteomics , Substrate Specificity , Voltage-Dependent Anion Channel 2/deficiency , Voltage-Dependent Anion Channel 2/genetics
9.
PLoS Genet ; 9(6): e1003569, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23818866

ABSTRACT

Known protein coding gene exons compose less than 3% of the human genome. The remaining 97% is largely uncharted territory, with only a small fraction characterized. The recent observation of transcription in this intergenic territory has stimulated debate about the extent of intergenic transcription and whether these intergenic RNAs are functional. Here we directly observed with a large set of RNA-seq data covering a wide array of human tissue types that the majority of the genome is indeed transcribed, corroborating recent observations by the ENCODE project. Furthermore, using de novo transcriptome assembly of this RNA-seq data, we found that intergenic regions encode far more long intergenic noncoding RNAs (lincRNAs) than previously described, helping to resolve the discrepancy between the vast amount of observed intergenic transcription and the limited number of previously known lincRNAs. In total, we identified tens of thousands of putative lincRNAs expressed at a minimum of one copy per cell, significantly expanding upon prior lincRNA annotation sets. These lincRNAs are specifically regulated and conserved rather than being the product of transcriptional noise. In addition, lincRNAs are strongly enriched for trait-associated SNPs suggesting a new mechanism by which intergenic trait-associated regions may function. These findings will enable the discovery and interrogation of novel intergenic functional elements.


Subject(s)
DNA, Intergenic/genetics , RNA, Long Noncoding/genetics , Transcription, Genetic , DNA, Intergenic/isolation & purification , Exons , Genome, Human , High-Throughput Nucleotide Sequencing , Humans , Polymorphism, Single Nucleotide , RNA, Long Noncoding/isolation & purification
10.
J Am Chem Soc ; 134(42): 17428-31, 2012 Oct 24.
Article in English | MEDLINE | ID: mdl-23025473

ABSTRACT

Fluorogenic probes activated by bioorthogonal chemical reactions can enable biomolecule imaging in situations where it is not possible to wash away unbound probe. One challenge for the development of such probes is the a priori identification of structures that will undergo a dramatic fluorescence enhancement by virtue of the chemical transformation. With the aid of density functional theory calculations reported previously by Nagano and co-workers, we identified azidofluorescein derivatives that were predicted to undergo an increase in fluorescence quantum yield upon Cu-catalyzed or Cu-free cycloaddition with linear or cyclic alkynes, respectively. Four derivatives were experimentally verified in model reactions, and one, a 4-azidonaphthylfluorescein analogue, was further shown to label alkyne-functionalized proteins in vitro and glycoproteins on cells with excellent selectivity. The azidofluorescein derivative also enabled cell imaging under no-wash conditions with good signal above background. This work establishes a platform for the rational design of fluorogenic azide probes with spectral properties tailored for biological imaging.


Subject(s)
Fluoresceins/chemistry , Fluorescent Dyes/chemistry , Molecular Imaging , Animals , CHO Cells , Cricetinae , Fluoresceins/chemical synthesis , Molecular Structure , Quantum Theory
11.
Mol Endocrinol ; 26(10): 1783-92, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22915829

ABSTRACT

The pancreatic ß-cell is critical for the maintenance of glycemic control. Knowing the compendium of genes expressed in ß-cells will further our understanding of this critical cell type and may allow the identification of future antidiabetes drug targets. Here, we report the use of next-generation sequencing to obtain nearly 1 billion reads from the polyadenylated RNA of islets and purified ß-cells from mice. These data reveal novel examples of ß-cell-specific splicing events, promoter usage, and over 1000 long intergenic noncoding RNA expressed in mouse ß-cells. Many of these long intergenic noncoding RNA are ß-cell specific, and we hypothesize that this large set of novel RNA may play important roles in ß-cell function. Our data demonstrate unique features of the ß-cell transcriptome.


Subject(s)
High-Throughput Nucleotide Sequencing , Insulin-Secreting Cells/metabolism , Transcriptome , Animals , Female , Gene Expression Profiling , Male , Mice , Mice, Transgenic , Organ Specificity , Promoter Regions, Genetic , RNA Splicing , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Analysis, RNA , Tryptophan Hydroxylase/genetics , Tryptophan Hydroxylase/metabolism
12.
Proc Natl Acad Sci U S A ; 108(8): 3141-6, 2011 Feb 22.
Article in English | MEDLINE | ID: mdl-21300897

ABSTRACT

Hundreds of mammalian nuclear and cytoplasmic proteins are reversibly glycosylated by O-linked ß-N-acetylglucosamine (O-GlcNAc) to regulate their function, localization, and stability. Despite its broad functional significance, the dynamic and posttranslational nature of O-GlcNAc signaling makes it challenging to study using traditional molecular and cell biological techniques alone. Here, we report that metabolic cross-talk between the N-acetylgalactosamine salvage and O-GlcNAcylation pathways can be exploited for the tagging and identification of O-GlcNAcylated proteins. We found that N-azidoacetylgalactosamine (GalNAz) is converted by endogenous mammalian biosynthetic enzymes to UDP-GalNAz and then epimerized to UDP-N-azidoacetylglucosamine (GlcNAz). O-GlcNAc transferase accepts UDP-GlcNAz as a nucleotide-sugar donor, appending an azidosugar onto its native substrates, which can then be detected by covalent labeling using azide-reactive chemical probes. In a proof-of-principle proteomics experiment, we used metabolic GalNAz labeling of human cells and a bioorthogonal chemical probe to affinity-purify and identify numerous O-GlcNAcylated proteins. Our work provides a blueprint for a wide variety of future chemical approaches to identify, visualize, and characterize dynamic O-GlcNAc signaling.


Subject(s)
Acetylgalactosamine/metabolism , Acetylglucosamine/metabolism , Affinity Labels , Metabolic Networks and Pathways , Receptor Cross-Talk , Cell Line , Chromatography, Affinity , Glycosylation , Humans , Methods , Protein Processing, Post-Translational
14.
Biochemistry ; 48(14): 3068-77, 2009 Apr 14.
Article in English | MEDLINE | ID: mdl-19256534

ABSTRACT

The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC catalyzes the committed reaction of lipid A (endotoxin) biosynthesis in Gram-negative bacteria and is a validated antibiotic target. Although several previously described compounds bind to the unique acyl chain binding passage of LpxC with high affinity, strategies to target the enzyme's UDP-binding site have not been reported. Here the identification of a series of uridine-based LpxC inhibitors is presented. The most potent examined, 1-68A, is a pH-dependent, two-step, covalent inhibitor of Escherichia coli LpxC that competes with UDP to bind the enzyme in the first step of inhibition. Compound 1-68A exhibits a K(I) of 54 muM and a maximal rate of inactivation (k(inact)) of 1.7 min(-1) at pH 7.4. Dithiothreitol, glutathione and the C207A mutant of E. coli LpxC prevent the formation of a covalent complex by 1-68A, suggesting a role for Cys-207 in inhibition. The inhibitory activity of 1-68A and a panel of synthetic analogues identified moieties necessary for inhibition. 1-68A and a 2-dehydroxy analogue, 1-68Aa, inhibit several purified LpxC orthologues. These compounds may provide new scaffolds for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Anti-Bacterial Agents/chemistry , Uridine/analogs & derivatives , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Escherichia coli/drug effects , Escherichia coli Proteins/drug effects , Kinetics , Structure-Activity Relationship , Uridine/pharmacology
16.
FASEB J ; 22(3): 721-32, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17971398

ABSTRACT

Increased levels of circulating saturated free fatty acids, such as palmitate, have been implicated in the etiology of type II diabetes and cancer. In addition to being a constituent of glycerolipids and a source of energy, palmitate also covalently attaches to numerous cellular proteins via a process named palmitoylation. Recognized for its roles in membrane tethering, cellular signaling, and protein trafficking, palmitoylation is also emerging as a potential regulator of metabolism. Indeed, we showed previously that the acylation of two mitochondrial proteins at their active site cysteine residues result in their inhibition. Herein, we sought to identify other palmitoylated proteins in mitochondria using a nonradioactive bio-orthogonal azido-palmitate analog that can be selectively derivatized with various tagged triarylphosphines. Our results show that, like palmitate, incorporation of azido-palmitate occurred on mitochondrial proteins via thioester bonds at sites that could be competed out by palmitoyl-CoA. Using this method, we identified 21 putative palmitoylated proteins in the rat liver mitochondrial matrix, a compartment not recognized for its content in palmitoylated proteins, and confirmed the palmitoylation of newly identified mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase. We postulate that covalent modification and perhaps inhibition of various mitochondrial enzymes by palmitoyl-CoA could lead to the metabolic impairments found in obesity-related diseases.


Subject(s)
Acyl Coenzyme A/chemistry , Azides/chemistry , Fatty Acids/chemistry , Lipoylation , Mitochondrial Proteins/metabolism , Palmitic Acid/metabolism , Acyl Coenzyme A/biosynthesis , Animals , Azides/metabolism , Cells, Cultured , Fatty Acids/metabolism , Hepatocytes/metabolism , Humans , Hydroxymethylglutaryl-CoA Synthase/metabolism , Mitochondria, Liver/enzymology , Mitochondrial Proteins/chemistry , Molecular Structure , Palmitic Acid/chemistry , Rats
18.
Methods Enzymol ; 415: 230-50, 2006.
Article in English | MEDLINE | ID: mdl-17116478

ABSTRACT

The staggering complexity of glycans renders their analysis extraordinarily difficult, particularly in living systems. A recently developed technology, termed metabolic oligosaccharide engineering, enables glycan labeling with probes for visualization in cells and living animals, and enrichment of specific glycoconjugate types for proteomic analysis. This technology involves metabolic labeling of glycans with a specifically reactive, abiotic functional group, the azide. Azido sugars are fed to cells and integrated by the glycan biosynthetic machinery into various glycoconjugates. The azido sugars are then covalently tagged, either ex vivo or in vivo, using one of two azide-specific chemistries: the Staudinger ligation, or the strain-promoted [3+2] cycloaddition. These reactions can be used to tag glycans with imaging probes or epitope tags, thus enabling the visualization or enrichment of glycoconjugates. Applications to noninvasive imaging and glycoproteomic analyses are discussed.


Subject(s)
Azides/chemistry , Indicators and Reagents/chemistry , Polysaccharides , Proteome/analysis , Proteomics/methods , Animals , Azides/metabolism , Carbohydrate Conformation , Cells, Cultured , Glycoproteins/chemistry , Glycoproteins/metabolism , Mice , Molecular Sequence Data , Molecular Structure , Polysaccharides/chemistry , Polysaccharides/metabolism
19.
J Mass Spectrom ; 40(10): 1319-26, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16220468

ABSTRACT

Although cleavable detergents were first synthesized a number of years ago, they have only recently been successfully applied to problems involving biological molecules. Recent reports have demonstrated that these compounds are useful for applications involving both 2D PAGE and mass spectrometry. However, most cleavable surfactants have utilized acid-labile functional groups to affect cleavage. In applications where extreme pH is required, acid cleavable detergents have limited usefulness. We report the synthesis of fluoride cleavable silane compounds and photolabile cinnamate esters as cleavable detergents having alternative cleavage chemistries than previously reported cleavable detergents. These compounds were applied to whole cell analysis using MALDI mass spectrometry, and it was demonstrated that their use results in an increase in the number of proteins analyzed by increasing protein solubility.


Subject(s)
Cell Line, Tumor/chemistry , Detergents/chemistry , Detergents/chemical synthesis , Membrane Proteins/chemistry , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Cell Line, Tumor/pathology , Humans , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...